Personalized pancreatic cancer vaccines with pembrolizumab
Treatments studied
Part of Cancer clinical trials.
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent and follow the study plan
- You have advanced pancreatic cancer (locally advanced, recurrent, or metastatic) confirmed by tumor testing, and standard treatment has failed or isn’t suitable
- Your tumor tissue must be enough for testing, and it must show at least one mutation that matches your immune type (HLA)
- You must be generally well enough (ECOG 0–1) and live for at least 4 months
- You must have measurable tumors on scans, and have adequate blood/organ function without certain medicines or transfusions around screening
- You must test negative for major viral infections and syphilis at baseline (CMV, EBV, HIV, HBV, HCV, syphilis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized neoantigen vaccine given along with an anti-PD1 drug (pembrolizumab) and chemotherapy after surgery for pancreatic cancer. The goal is to see if this combination can help prevent the cancer from coming back.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This trial tests a personalized cancer vaccine (ODI-2001) combined with standard chemotherapy in patients with advanced colon or pancreatic cancer that cannot be surgically removed. The vaccine is designed specifically for each patient's tumor to help their immune system fight the cancer.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
This trial tests a personalized mRNA vaccine made from your tumor’s unique genetic features. It is given after surgery to prevent the pancreatic cancer from coming back.
Hear when a new Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.